Realizing the promise.

We are at the cusp of a revolution in medicine. Synthetic biology is an entirely new strategy in drug development, affording us the opportunity to design selective and potent living medicines to treat disease. With a team of experienced scientists and executives at the helm, Synlogic is forging new ground to advance this approach and design novel therapeutics to treat unmet medical needs.


Aoife M. Brennan, MB, ChB

President, Chief Executive Officer, Chief Medical Officer

Todd Shegog

Chief Financial Officer

Paul Miller, PhD

Chief Scientific Officer

Caroline B. Kurtz, PhD

Head of Translational Sciences and Product Development

Adam Thomas

Chief Human Resources Officer

Maiken Keson-Brookes

General Counsel
Tony Awad

Antoine Awad

Head of Technical Operations